Simplex Trading’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Simplex Trading’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,000	Closed	-$7K	–	8267
2019 Q2	$7K	Buy	10,000 +9,583	+2,298%	+$10.7K	﹤0.01%	6335
2019 Q1	$0	Buy	+417	New	+$475	﹤0.01%	8282
2018 Q2	–	Sell	-2,384	Closed	-$8K	–	8197
2018 Q1	$8K	Buy	+2,384	New	+$10.1K	﹤0.01%	4280
2017 Q2	–	Sell	-6,819	Closed	-$65.7K	–	7198
2017 Q1	$73K	Buy	6,819 +651	+11%	+$6.65K	﹤0.01%	2025
2016 Q4	$51K	Buy	+6,168	New	+$54.6K	﹤0.01%	2142

Other funds holding NVLN

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

FSA

Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Simplex Trading's NVLN Position: Q3 2019 in Review

Simplex Trading sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2019, closing a stake of 10,000 shares — an estimated $7K sold.

Simplex Trading first reported a position in NVLN in Q4 2016 and held it in 5 quarters. The position peaked at $73K in Q1 2017. 31 funds tracked by Wall St. Rank hold NVLN as of Q3 2019.

Simplex Trading reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q3 2019 after selling out during the quarter.
Simplex Trading sold 10,000 Novelion Therapeutics Inc. Common Shares shares in Q3 2019, an estimated $7K.
Simplex Trading first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 5 quarters.
Simplex Trading's Novelion Therapeutics Inc. Common Shares position peaked at $73K in Q1 2017.
31 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2019.

Based on Simplex Trading's 13F filing for Q3 2019, filed 15 Oct 2019.